-
Closing Plenary Session examined highlights from the AACR Annual Meeting 2026
During the final session of the AACR Annual Meeting 2026, experts reviewed groundbreaking advances presented across the continuum of cancer research—identifying key takeaways from the plethora of basic/translational studies, population sciences research, and clinical trials presented throughout the conference.
-
Fourth Plenary Session explored generational trends and possible drivers of early-onset cancers
Andrew T. Chan, MD, MPH, chaired the session, which examined the rising incidence of early-onset cancers and the potential contributions of obesity, bacterial exposures, and weaning to this trend.
-
Fifth Plenary Session spotlighted new treatment modalities transforming the oncology landscape
Katayoun Rezvani, MD, PhD, chaired the session, which shone a light on radiopharmaceuticals, next-generation biologics, and cellular immunotherapy as groundbreaking therapeutic modalities for cancer, with a focus on solid tumors.
-
Final New Drugs on the Horizon session completed the series with the last four novel molecules
Presenters described a first-in-class inhibitor of cyclin A/B-substrate interaction, a molecular glue degrader for the treatment of acute myeloid leukemia, a novel antibody-drug conjugate, and a dual T-cell agonist selective for a specific T-cell subtype.
-
Third Clinical Trials Plenary Session delved into next-generation cellular therapies and immunotherapies
Omar Nadeem, MD, discussed results of the CAR-PRISM trial, which evaluated the use of ciltacabtagene autoleucel in patients with high-risk smoldering myeloma, an early, asymptomatic form of multiple myeloma.
-
Fourth Clinical Trials Plenary Session highlighted emerging developments in immunotherapy
Alberto Giovanni Leone, MD, shared results from cohort two of the single-arm, nonrandomized phase II INFINITY clinical trial assessing a combination treatment of tremelimumab and durvalumab.
Meet the 2026 NextGen Stars
